29

May2020

Delay of Implementation of PMPRB Amended Regulations to January 1, 2021

PDCI Market Access understands from multiple sources that Health Canada is reaching out to stakeholder groups today to confirm the delay of the implementation of the PMPRB amended Regulations to January 1, 2021. Official publication of the delay in Canada Gazette to follow (likely in CG2 on June ... Read More

19

Mar2020

PMPRB Has Now Published Submissions Received as Part of its Draft Guidelines Consultation

The full list of submissions can be found here under the Submissions tab at the bottom of the page. Background: On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. The PMPRB ... Read More

10

Mar2020

PMPRB Cancellation of March 18th Policy Forum

PMPRB Cancellation of March 18th Policy Forum The Patented Medicines Prices Review Board (PMPRB) has announced the cancellation of its Policy Forum expected to be held on March 18th, 2020 amid the evolving COVID-19 situation. In order to provide stakeholders with an opportunity to convey information that may ... Read More

25

Feb2020

Sharing Responses to the Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation

On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. Since then, the PMPRB has engaged with stakeholders to obtain feedback on its proposed pricing Guidelines. The consultation period closed on February 14, ... Read More

13

Feb2020

PDCI Analysis Estimates Impact of PMPRB Draft Guidelines to be up to $41.8 Billion

Following the publication of the PMPRB Draft Guidelines on Nov 21, 2019, PDCI undertook an analysis to critically assess the impact of the PMPRB regulatory changes published in August 2019, as proposed to be implemented in the Draft Guidelines. Top-Line Summary The PMPRB regulatory changes and Draft ... Read More

14

Jan2020

PMPRB and “Zero-dollar” Sales

W. Neil Palmer In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More

06

Jan2020

PMPRB Consultation Update and Patentee Webinar

Recently, the deadline for providing written submissions on the PMPRB’s proposed new Guidelines was extended until January 31, 2020. As part of the ongoing consultation process, the PMPRB has reserved three days in January for bilateral meetings with individual patentees: January 8, 9, and 10, 2020. Meetings will be scheduled on ... Read More

26

Nov2019

PDCI Market Access: PMPRB Reforms Briefing and Strategy Sessions (Toronto and Montreal)

REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members ... Read More

27

Aug2019

UPCOMING WEBINAR SEPTEMBER 4: 2019 PMPRB Regulation Amendments and Implications

PDCI and 3Sixty Public Affairs invites its industry clients, partners and colleagues to participate in a webinar on September 4, 2019 between 2:00pm to 3:00pm. This important session will cover the PMPRB price regulatory amendments and share insights on their implications for pharmaceutical market access. The session will provide an overview of ... Read More

19

Aug2019

HDAP 2020 Meeting Dates Released

The PMPRB has announced the 2020 meeting dates to the Human Drug Advisory Panel (HDAP)’s , releasing a total of four (4) dates, as per previous years. This corrected version of TargetPharma makes a distinction between the deadline for submitting the Product Monograph and the deadline for the Patentee's submission.... Read More